Recent Press Releases

December 2019

Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science

- Acquisition complements and expands Castle Creek clinical development pipeline to include gene therapy platform - - Strategic acquisition to [...]

September 2019

Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell

- Castle Creek will advance multiple late-stage clinical development programs targeting epidermolysis bullosa - PARSIPPANY, N.J., September 12, 2019 -- Castle [...]

June 2019

Castle Creek Pharmaceuticals Appoints Mary Spellman, M.D., as Chief Medical Officer and Senior Vice President of Research & Development

PARSIPPANY, N.J., June 3, 2019 -- Castle Creek Pharmaceuticals, LLC., a privately held biopharmaceutical company developing innovative therapies for patients [...]

April 2019

Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

- Fibrocell to receive up to $135 million, including up to $30 million in upfront, near-term and development payments and [...]

October 2018

Castle Creek Pharma Announces $71.8 Million in New Investment to Expand Research for Rare Dermatologic Conditions

Castle Creek Pharma secures new investment from Fidelity Management & Research Company and Valor Equity Partners towards the late stage [...]

August 2018

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex

Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) in ongoing DELIVERS study PARSIPPANY, NJ – August 9, 2018 – Castle [...]

June 2018

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to [...]

May 2018

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa PARSIPPANY, N.J., May 16, [...]

January 2018

Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit

Biopharma company developing therapies for orphan dermatologic conditions to present during Entrepreneurial Company Showcase. PARSIPPANY, NJ – January 3, 2018 [...]

October 2017

Castle Creek Pharmaceuticals Announces Hiring of Dr. Amir Tavakkol as Executive Vice President and Chief Development Officer

PARSIPPANY, NJ – October 30, 2017 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to [...]

© 2016 Castle Creek Pharma  -  Terms & Conditions  -  Privacy Policy

Powered by AmericanEagle.com